Figure S6 from Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G₁–S Transition

Darolutamide and docetaxel pharmacokinetics in PC346C bearing mice, related to Figure 2A-C. A: Mean systemic darolutamide concentrations in PC346C bearing mice treated with darolutamide, with or without docetaxel (n=8 and n=9 per group, respectively) directly after oral darolutamide administration at treatment initiation (start), 2 weeks or 4 weeks after treatment initiation and at time of mouse sacrifice (end). B: Mean systemic docetaxel concentrations in PC346C bearing mice treated with docetaxel, with or without darolutamide (n=8 per group) directly after i.v. docetaxel administration.